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Early-onset methamphetamine use increases the lifetime prevalence of methamphetamine 
dependence. An earlier onset of methamphetamine use leads to greater damage to the 
terminal ends of serotonin neurons, more reduction in serotonin transporter (5-HTT) density, 
and an increased propensity toward further methamphetamine use. Because the 5-HTT-
linked polymorphic region (5′-HTTLPR) within the promoter region of the 5-HTT gene leads 
to differential expression of the 5-HTT, we examined, for the first time, whether there is a 
differential association between the long (L) and short (S) alleles of the 5′-HTTLPR and the age 
of first methamphetamine use (AMU). The study included 120 methamphetamine-dependent 
adults of European descent. Diagnosis of methamphetamine dependence and AMU were 
collected using structured questionnaires, and the 5′-HTTLPR genotypes were determined using 
the polymerase chain reaction–restriction fragment length polymorphism method. Statistical 
analysis with the general linear model detected a significant interactive effect of 5′-HTTLPR 
genotypes (SS vs. L-carriers) and gender, associated with AMU (F = 3.99; p = 0.048). Further 
analysis of 5′-HTTLPR effects on AMU in males and females separately showed that the SS 
genotype compared with L-carriers had about two times greater risk of an earlier onset of 
methamphetamine use in men (hazard ratio = 1.839; 95% confidence interval = 1.042–3.246; 
p = 0.036) but not in women. Together, our findings in this preliminary study suggest a greater 
risk for earlier onset methamphetamine use associated with the SS genotype of the 5′-HTTLPR 
among methamphetamine-dependent Caucasian males.
Keywords: methamphetamine, age of onset, serotonin transporter, genotype, serotonin transporter-linked 
polymorphic region
Edited by:
Lorenzo Leggio, Brown University, USA
Reviewed by:
Lorenzo Leggio, Brown University, USA
George Kenna, Brown University, USA
*Correspondence:
Bankole A. Johnson, Department of 
Psychiatry and Neurobehavioral 
Sciences, University of Virginia, 
P.O. Box 800623, Charlottesville, VA 
22908-0623, USA.  
e-mail: bankolejohnson@virginia.edu
†Investigators in the 
Methamphetamine Study Group are 
listed in an Appendix.
have raised additional concern about the increasing prevalence 
of methamphetamine addiction (Ehlers et al., 2007; Johnson 
et al., 2008).
Several studies conducted in various countries, and with different 
ethnic populations, have reported an increased prevalence of adult 
methamphetamine dependence when the onset of methamphetamine 
use occurred in adolescence (Nordahl et al., 2003). The progression 
from first-time drug use to the development of dependence does, 
however, depend upon the interplay of both genetic and environmen-
tal factors (Goldman et al., 2005; McGue et al., 2006); therefore, not 
all adolescents who experiment with methamphetamine progress to 
methamphetamine dependence as adults (Fowler et al., 2007).
The importance of genetic factors has been highlighted by Ehlers 
et al. (2007), who showed, in a relatively homogenous population of 
Native Americans in Southwest California, that the liability toward 
IntroductIon
Methamphetamine is a highly addictive central nervous system 
stimulant, and both current and recently abstinent chronic meth-
amphetamine-dependent individuals can develop irreversible 
structural and neurochemical changes in the brain with long-lasting 
cognitive and motor deficits (Seiden and Ricaurte, 1987; Chang 
et al., 2002; Thompson et al., 2004).
Methamphetamine dependence is on the rise in the United 
States and other parts of the world (Winslow et al., 2007). 
According to surveys funded by the National Institute on Drug 
Abuse (NIDA) in 2005, 10.4 million Americans aged 12 years and 
older and 4.5% of 12th graders had used methamphetamine at 
least once in their lifetime (NIDA, 2006). Increased production 
and spread of methamphetamine use to other parts of the coun-
try from its traditional endemic areas in the West and Midwest 
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thalamocortical circuits from the nucleus ventralis anterior also 
innervate the anterior cingulate, an important site for the expres-
sion of the drive to use stimulants (Goldstein et al., 2009; Fineberg 
et al., 2010). Hence, the genetic effect of alterations in 5-HTT func-
tion during embryonic development might exert a morphogenic 
influence that predisposes to stimulant-taking behavior.
Evidence from another line of research supports the finding that 
morphometric and functional changes in the limbic system (for a 
review, see Dawes and Johnson, 2004), particularly the amygdala, 
an important site for emotional learning and the conditioning of 
impulsivity and response to fear (Paton et al., 2006), can be associ-
ated with alterations in 5′-HTTLPR function. Healthy individu-
als with the S allele of the 5′-HTTLPR appear to have a reduced 
volume of the amygdala as well as the anterior cingulate (Pezawas 
et al., 2005) and, behaviorally, a reduced ability to process emotion 
appropriately. Pacheco et al. (2009), using magnetic resonance 
imaging, also showed a decreased white matter connection via 
the uncinate fasciculus between the amygdala and the pre-frontal 
cortex in S variants. Furthermore, this effect of the 5′-HTTLPR 
genotype might differ by sex and race (Williams et al., 2003). 
Indeed, individuals with the S allele have been associated with 
reduced 5-HT turnover and 5-hydroxyindoleacetic acid levels in 
men but not in women. Consistently, the S allele has been associ-
ated with greater impulsivity in Caucasian men (Walderhaug et al., 
2010). This is important because Semple et al. (2005) reported 
that heightened impulsivity, a trait that is associated with allelic 
variation at the 5′-HTTLPR (Walderhaug et al., 2010), predisposes 
to the initiation of methamphetamine use (Munafò et al., 2003; 
Semple et al., 2005), although it has been debated whether it is 
a cause or a consequence of drug use. Taken together, these data 
would lead to the speculation that individuals with the S com-
pared with the L allele of the 5′-HTTLPR might be more prone to 
using stimulants, especially early in life, with a greater likelihood 
in Caucasian men.
The 5-HT system is important for the pharmacotoxic effects of 
methamphetamine since its use is associated with damage to 5-HT 
neurons by degrading their terminal ends (Ricaurte et al., 1980; 
Krasnova and Cadet, 2009). Methamphetamine intake also inhibits 
5-HTT protein expression, particularly in the orbitofrontal cortex, 
even though there also is damage to dopaminergic neurons (Kish 
et al., 2009) and a decrease in vesicular monoamine transporter 
function (Brown et al., 2000). Consistently, human brain imag-
ing studies also have shown that chronic methamphetamine users 
can exhibit significantly reduced 5-HTT densities, an indication of 
terminal neuronal damage, in different brain regions (Sekine et al., 
2006). Because these reductions in 5-HTT density occur in a time- 
and concentration-dependent manner, individuals with the earliest 
onset and greatest use of methamphetamine can be expected to 
experience the most impairment of 5-HT function. We speculate 
that this would lead to a feed-forward effect whereby those with the 
S allele are more prone to impulsivity and an earlier onset of meth-
amphetamine use, the prolonged use of methamphetamine results 
in greater 5-HT damage, and “normalizing” 5-HT neurotransmis-
sion is achieved only by taking more methamphetamine.
The present study examined whether allelic variation of the 
5′-HTTLPR was associated with age of onset of methamphetamine 
use in Caucasian men and women.
the initiation of stimulant use is highly heritable at an estimated 
rate of 38%. Understanding the nature of the genetic factors that 
increase the risk of stimulant initiation can aid in appropriate 
screening and early intervention for those who are environmen-
tally vulnerable to methamphetamine exposure, and can facilitate 
the development of medications targeted toward the treatment of 
those who become dependent.
Serotonin (5-HT) neurons are tonic inhibitors of dopamine 
neurons in the central nervous system (Johnson, 2000). Therefore, 
the degradation of 5-HT neurons can lead to a rise in extracellular 
dopamine levels (Nordahl et al., 2003), which in turn increases the 
individual’s behavioral propensity toward further methampheta-
mine use (Volkow and Li, 2004).
Of the mechanisms that control synaptic 5-HT function, per-
haps the most compelling relates to the functional state of the pre-
synaptic 5-HT transporter (5-HTT). The 5-HTT is responsible 
for removing 5-HT from the synaptic cleft (Lesch et al., 2002). 
Indeed, up to 60% of neuronal 5-HT function is gated by the 
5-HTT. Synaptic clearance of 5-HT is determined by the number 
of 5-HTTs expressed at the pre-synaptic surface and the affinity of 
5-HTTs to 5-HT (Beckman and Quick, 1998).
The 5-HTT gene is found at the SLC6A4 locus on chromosome 
17q11.1-q12, and its 5′-regulatory promoter region contains a func-
tional polymorphism known as the 5-HTT-linked polymorphic 
region (5′-HTTLPR) (Heils et al., 1996, 1997). This polymorphism 
is an insertion/deletion mutation in which the long (L) variant has 
44 bp that are absent in the short (S) variant. The S-allelic variant 
of the 5′-HTTLPR is associated with reduced transcription rates in 
both lymphoblasts and in vitro cultured cells and, consequently, with 
decreased 5-HT turnover (Lesch et al., 1996; Hranilovic et al., 2004; 
Javors et al., 2005). In the general population, S-carriers, compared 
with the LL genotype, are associated with reduced 5-HT uptake 
into human platelets (Greenberg et al., 1999) and  lymphoblasts 
(Lesch et al., 1996) and reduced [123I]2 beta- carboxymethoxy-3 
beta-(4-iodophenyl)tropane (β-CIT) binding in human raphe 
nuclei (Heinz et al., 2000). Hence, healthy individuals with the SS 
genotype have reduced uptake and, presumably, greater intrasy-
naptic 5-HT levels and 5-HT neurotransmission compared with 
L-carriers (Heils et al., 1996; Lesch et al., 1996).
Animal studies have shown that genetic alterations that affect 
5-HT levels during embryonic development alter the formation of 
barrels in the somatosensory cortex (i.e., post-central gyrus) (Cases 
et al., 1996; Vitalis et al., 1998; Persico et al., 2001; Xu et al., 2004). 
The somatosensory cortex is innervated by thalamocortical circuits 
(Nordquist and Oreland, 2010). These circuits, although originally 
glutaminergic, express 5-HT during embryonic development 
through the 5-HTT and, therefore, exhibit 5-HT uptake, vesicular 
storage, and release from nerve terminals (Ausó et al., 2001). 5-HT 
uptake rather than release appears critical to the development of 
proper branching arbors at their terminal ends. It is, therefore, 
tempting for us to speculate that the S compared with the L allele, 
being associated with less efficient transcription of the 5-HT gene 
and, therefore, reduced uptake (Lesch et al., 1996; Hranilovic et al., 
2004), would be associated with less development of the thalamo-
cortical afferents that serve the somatosensory cortex. In humans, 
the somatosensory cortex is associated with the appreciation of 
touch, which can have emotional correlates. Perhaps more directly, 
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GenotypInG
DNA was extracted using a Gentra Puregene® kit (QIAGEN 
Inc., Valencia, CA, USA). Fifty nanograms of genomic DNA 
was polymerase chain reaction amplified for the 5′-HTTLPR 
44-bp promoter-region repeat polymorphism using the prim-
ers 5′-TCCTCCG CTTTGGCGCCTCTTCC-3′ (forward) and 
5′-TGGGG GTTGCAGGGGAGATCCTG-3′ (reverse) in a 20-μl 
final volume with 2.5 U of BIOLASE™ DNA polymerase (Bioline, 
London, UK), 1× NH
4
 reaction buffer, 0.5 mM MgCl
2
, 0.8 mM 
deoxynucleotide triphosphates, dimethyl sulfoxide, and 100 nM 
of each primer. The thermal cycling included: initial denaturation 
at 95°C for 15 min; 45 cycles of 94°C for 30 s, 65.5°C for 90 s, and 
72°C for 1 min; a final extension of 72°C for 10 min, and a termi-
nal hold at 4°C. The alleles for the 5′-HTTLPR were separated by 
gel electrophoresis using 3% agarose (Cambrex, Rockland, ME, 
USA) and visualized by an ethidium bromide/ultraviolet detec-
tion system.
StatIStIcal analySIS
Considering that the majority of participants in both trials 
were of European descent, as well as the potential confounding 
effects of ethnicity on the association analysis, only participants 
of European descent were included in the statistical analyses that 
are reported in this study. We employed a general linear regres-
sion model (GLM) to analyze 5′-HTTLPR genotype associations 
with the age of first methamphetamine use (AMU) under the 
additive, dominant, and recessive genetic models. As several pre-
vious studies have shown a gender difference in both metham-
phetamine use and methamphetamine-induced neuropathology 
(Brecht et al., 2004; Scott et al., 2007; Dluzen et al., 2010), we 
included gender in all genetic models to test for the main effects 
of gender and genotype as well as the interactive gender-by-
genotype effect. Next, based on the GLM analysis results, we used 
the Cox proportional-hazards model to assess the relative risk of 
an earlier onset of methamphetamine use for the SS genotype 
compared with L-carriers of the 5′-HTTLPR in males and females 
separately. Additionally, we obtained Kaplan–Meier estimates of 
the probability of not yet starting methamphetamine use as a 
function of age (years) for SS and L-carrier males and females. 
A log-rank test was used to compare the shapes of these age of 
onset curves. All analyses were performed using SAS statistical 
software (version 9.1; SAS Institute Inc., Cary, NC, USA).
reSultS
Table 1 shows the demographic information for the subjects from 
the pooled sample and each trial. DNA samples from 141 meth-
amphetamine-dependent subjects aged between 18 and 60 years 
were genotyped in this study.
The 5′-HTTLPR genotype distribution in the pooled 
Caucasian sample did not deviate from Hardy–Weinberg equi-
librium expectations. As shown in Table 2, there was a significant 
effect of gender and 5′-HTTLPR genotypes on AMU when the 
SS genotype group was compared with L-carriers. In Caucasian 
males, the SS homozygotes showed a significantly higher risk 
of an earlier onset of methamphetamine use compared with 
L-carriers (hazard ratio = 1.839; 95% confidence interval 
[CI] = 1.042–3.246; p = 0.036), while the difference between 
MaterIalS and MethodS
SubjectS
One hundred forty-one subjects, who were enrolled in two 
 multi-site clinical trials (Trials 1 and 2) for the treatment of meth-
amphetamine dependence, and who consented to participate in 
genetic analyses, were included in this study. Of the 141 subjects, 
36 were from Trial 1 (Johnson et al., 2008) and 105 were from Trial 
2 (data not yet published). All subjects were at least 18 years of 
age and diagnosed as methamphetamine dependent by Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) 
criteria (American Psychiatric Association, 1994). The enrollment 
requirements were similar for both trials. The enrolled subjects 
were required to have at least one methamphetamine-positive urine 
specimen during the 2-week baseline period. They were in good 
physical health as determined by physical and laboratory examina-
tions (i.e., hematological assessment, biochemistry, and urinalysis). 
Exclusion criteria were current dependence on any psychoactive 
substance (as defined by DSM-IV criteria) besides methampheta-
mine, nicotine, or marijuana, or physiological dependence on 
alcohol or a sedative–hypnotic, e.g., a benzodiazepine requiring 
medical detoxification. We also excluded individuals with current 
diagnoses of anxiety, affective, or psychotic disorders. We did not 
study individuals who: were mandated by the courts to be treated 
for methamphetamine dependence, were pregnant or not using an 
acceptable form of contraception (i.e., oral contraceptive, hormo-
nal or surgical implant, sterilization, or spermicide and barrier), 
were taking psychotropic medication, were using opiate substitutes 
within 2 months of enrollment, were asthmatic, or had AIDS.
The following clinical sites participated in each trial: Trial 1: The 
University of Texas Health Science Center at San Antonio, TX, USA; 
Iowa Lutheran Hospital, Des Moines, IA, USA; South Bay Treatment 
Center, San Diego, CA, USA, and the University of Missouri-Kansas 
City, MO, USA. Trial 1 was coordinated by the Integrated Substance 
Abuse Programs at the University of California, Los Angeles, CA, USA. 
Study subjects were recruited between August 2002 and July 2003 
by newspaper, television, or radio advertisements. Trial 2: University 
of Virginia, Charlottesville, VA, USA; University of California, Los 
Angeles, CA, USA; START Research and Treatment, Kansas City, MO, 
USA; University of Hawaii, Honolulu, HI, USA; South Bay Treatment 
Center, San Diego, CA, USA; Iowa Lutheran Hospital, Des Moines, IA, 
USA; Matrix Institute, West Los Angeles, CA, USA, and Salt Lake City 
Health Care System, Department of Veterans Affairs, Salt Lake City, 
UT, USA. Both trials were approved by the appropriate participating 
Institutional Review Boards.
After obtaining written informed consent, and prior to the 
subjects’ enrollment in the clinical trial, we determined psychiat-
ric diagnosis using the Structured Clinical Interview for DSM-IV 
(First et al., 1994) and age of onset of methamphetamine use using 
the Addiction Severity Index-Lite (Cacciola et al., 2007). Other 
structured measures were collected at enrollment and at scheduled 
intervals during the clinical trial, as reported elsewhere (Johnson 
et al., 2008).
collectIon of blood SaMpleS for GenotypInG
Approximately 10 ml of blood was drawn from each subject to 
obtain white blood cells for the determination of 5′-HTTLPR 
genotypes.
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Table 1 | Demographic information on the subjects included in the study.
 Pooled subjects Subjects from Trial 1 Subjects from Trial 2
Number of subjects who 
consented for genetic analyses
141 36 105
Self-identified ethnicity: N (%) 121 Caucasians (85%) 28 Caucasians (78%) 93 Caucasians (89%)
20 Non-Caucasians (3 Asians,  
6 Hispanics, 2 African Americans,  
8 of mixed ethnicity, 1 of unknown 
ethnicity) (15%)
8 Non-Caucasians (2 Asians,  
6 Hispanics) (22%)
12 Non-Caucasians (1 Asian,  
2 African Americans, 8 of mixed 
ethnicity, 1 of unknown ethnicity) 
(11%)
Age of onset: Mean ± SEM All ethnicities: 23.35 ± 0.87 All ethnicities: 21.19 ± 0.87 All ethnicities: 24.09 ± 0.78
Caucasians: 23.99 ± 0.70 Caucasians: 21.14 ± 0.94 Caucasians: 24.81 ± 0.84
Gender: N (%) All ethnicities: 47 females (33%)  
94 males (67%)
All ethnicities: 11 females (31%) 
25 males (69%)
All ethnicities: 36 females (34%) 
69 males (66%)
Caucasians: 42 females (35%)  
79 males (65%)
Caucasians: 9 females (32%)  
19 males (68%)
Caucasians: 33 females (35%) 
60 males (65%)
5′-HTTLPR genotype distribution 
in subjects of all ethnicities: N (%)
LL – 40 (65% male; 35% female)
LS – 71 (68% male; 32% female)
LL – 6 (33% male; 67% female) 
LS – 19 (74% male; 26% female)
LL – 34 (71% male; 29% female)
LS – 52 (65% male; 35% female)
SS – 30 (67% male; 33% female) SS – 11 (82% male; 18% female) SS – 19 (58% male; 42% female)
5′-HTTLPR genotype distribution 
in Caucasians: N (%)
LL – 36 (64% male; 36% female)
LS – 59 (66% male; 34% female)
LL – 5 (40% male; 60% female)
LS – 16 (69% male; 31% female)
LL – 31 (68% male; 32% female)
LS – 43 (65% male; 35% female)
SS – 26 (65% male; 35% female) SS – 7 (86% male; 14% female) SS – 19 (58% male; 42% female)
Table 2 | Results of general linear model for the 5′-HTTLPR genotypic 
associations with age of onset of methamphetamine use.
Genotypes Predictor df Sum of F-value p-value 
comparison variable  squares
LL, LS, and SS Sex 1 38.94 0.660 0.419
 Genotype 2 7.34 0.060 0.940
 Sex × genotype 2 233.97 1.980 0.143
LL vs. S-carriers Sex 1 0.36 0.010 0.938
 Genotype 1 4.89 0.080 0.776
 Sex × genotype 1 37.01 0.620 0.433
L-carriers vs. SS Sex 1 112.37 1.930 0.167
 Genotype 1 0.96 0.020 0.898
 Sex × genotype 1 232.10 3.990 0.048
df, degrees of freedom.
SS and L-carrier female subjects was not  significant (hazard 
ratio = 0.719; 95% CI = 0.329–1.573; p = 0.409). The compari-
sons for the differences among the three genotypic groups or 
between the LL genotype and S-carriers did not show a signifi-
cant risk effect on AMU, suggesting a dominant effect of the L 
allele over the S allele.
Using the Kaplan–Meier method, we found that males with the 
SS genotype, compared with their L-carrier counterparts, became 
dependent on methamphetamine significantly earlier (log-rank, 
all p values = 0.027; Figure 1A). We, however, found no significant 
difference in AMU between the SS and L-carrier genotypic groups 
among females (p = 0.390; Figure 1B).
dIScuSSIon
Our results suggest that among methamphetamine-dependent 
Caucasian males, possession of the SS genotype in the 5′-HTTLPR, 
compared with their L-carrier counterparts, was associated with 
about a two times greater risk of having had an earlier onset of 
methamphetamine use.
Interestingly, in this study, the SS genotype was associated with 
an early onset of methamphetamine use in men. Indeed, this is 
explainable as results from animal studies have constantly demon-
strated a protective role of estrogen on methamphetamine-induced 
5-HT and dopamine depletion; male mice and ovariectomized 
female mice were shown to have significantly depleted 5-HT and 
dopamine levels compared with female mice (Yu and Liao, 2000). 
It is, therefore, tempting to speculate that methamphetamine use 
in males might be associated with alterations in intrasynaptic 
5-HT levels due to polymorphic differences at the 5′-HTTLPR, 
with SS subjects having an earlier onset of methamphetamine use 
than L-carriers. These results also are consistent with the finding 
of greater impulsivity in male Caucasians with the S allele of the 
5′-HTTLPR (Walderhaug et al., 2010).
This study had four limitations. First, this study was only a 
preliminary analysis with a modest sample size that did not pro-
vide sufficient statistical power to examine ethnic populations 
other than Caucasians. Large-scale studies are, therefore, needed 
to replicate and extend our findings. Second, because of the cross-
sectional nature of the study, we were unable to assess how genetic 
variation in the 5′-HTTLPR interacted with the progression of 
methamphetamine use over time. Third, our cohort was composed 
of methamphetamine-dependent individuals who were seeking 
treatment. Since treatment seekers can vary in pathophysiology 
from those in the community, often being more motivated and 
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